ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

<p>ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data Immix Biopharma, Inc. (NASDAQ:IMMX) Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.  …</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/immixbio-initiates-imx-110-gmp-manufacturing-scale-up-potentially-accelerating-clinical-trial-data/">ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>